Reported CRISPR treatment milestones and the challenge of wider access

One post says the FDA expanded Casgevy's approval in July 2026 to children as young as two with sickle cell disease or beta-thalassemia. It also cites a personalized CRISPR treatment in 2025 and Germany's first routine-care CRISPR patient, who it says became transfusion-free within four months. Another post calls biotech “overdelivering,” pointing to AI protein design and cellular rejuvenation being tested in humans. The first post warns that cost, manufacturing capacity and equitable access remain hurdles.